
"Sector" = median of Consumer Defensive across 72 companies
Coca-Cola Europacific Partners (CCEP) is one of the world's largest independent bottlers and distributor of The Coca-Cola Company's products. It operates across Western Europe, Australia, New Zealand, and parts of Asia, producing, packaging, and selling a wide range of non-alcoholic beverages including sparkling soft drinks, juices, waters, sports drinks, and ready-to-drink coffee. The company was formed through mergers of Coca-Cola Enterprises, Coca-Cola Iberian Partners, and Coca-Cola Erfrischungsgetränke, and later expanded into the Pacific region.
CCEP generates revenue primarily by manufacturing and distributing beverages under license from The Coca-Cola Company. Its business model focuses on efficient production, logistics, and route-to-market capabilities. Revenue is driven by volume sales and price/mix improvements across its portfolio. The company also benefits from long-term contracts with Coca-Cola, providing stable cash flows. Recent quarters show consistent revenue growth, with 2025Q4 revenue reaching €10.63 billion.
CCEP operates in the non-alcoholic beverage industry, a highly competitive sector with major players like PepsiCo and Keurig Dr Pepper. The company holds a strong position as the largest Coca-Cola bottler by revenue, benefiting from exclusive territorial rights and scale advantages. Its focus on cost efficiency, innovation, and sustainability helps maintain margins, with operating margin at 13.36% and profit margin at 8.13%.
CCEP's products are consumed by a broad consumer base, from individuals to businesses, across retail, foodservice, and vending channels. Key geographic markets include Western Europe (especially Spain, France, Germany, and the UK), Australia, New Zealand, and parts of Asia. The company's diversified geographic footprint reduces reliance on any single market, while its strong brand portfolio drives customer loyalty.
An auto-generated descriptive profile based on company data, for informational purposes only.
No 24-hour summary has been generated yet.
Latest saved period: December 2025 · 2025-12-31
Cash dividends by ex-date, not an investment recommendation.
| Ex-date | Amount | Payment date | Period |
|---|---|---|---|
| Nov 14, 2025 | $1.43 | Dec 3, 2025 | Semiannual |
| May 16, 2025 | $0.90 | May 27, 2025 | Semiannual |
| Nov 15, 2024 | $1.34 | Dec 3, 2024 | Semiannual |
| May 9, 2024 | $0.79 | May 23, 2024 | Semiannual |
| Nov 16, 2023 | $1.23 | Dec 5, 2023 | Semiannual |
| May 11, 2023 | $0.74 | May 25, 2023 | Semiannual |
| Nov 17, 2022 | $1.11 | Dec 7, 2022 | Semiannual |
| May 12, 2022 | $0.59 | May 26, 2022 | Quarterly |
| Nov 18, 2021 | $1.62 | Dec 6, 2021 | Annual |
| Nov 16, 2020 | $1.00 | Dec 1, 2020 | Annual |
| Nov 18, 2019 | $0.69 | Dec 3, 2019 | Semiannual |
| May 23, 2019 | $0.69 | Jun 6, 2019 | Quarterly |
| Nov 8, 2018 | $0.32 | Nov 20, 2018 | Quarterly |
| Aug 21, 2018 | $0.30 | Sep 6, 2018 | Quarterly |
| May 11, 2018 | $0.31 | May 29, 2018 | Quarterly |
| Feb 26, 2018 | $0.32 | Mar 15, 2018 | Quarterly |
| Nov 17, 2017 | $0.24 | Dec 4, 2017 | Quarterly |
| Aug 24, 2017 | $0.25 | Sep 11, 2017 | Quarterly |
| May 18, 2017 | $0.23 | Jun 5, 2017 | Quarterly |
| Apr 6, 2017 | $0.23 | Apr 24, 2017 | Quarterly |
| Dec 27, 2016 | $0.18 | Jan 13, 2017 | Quarterly |
| Sep 30, 2016 | $0.19 | Oct 17, 2016 | Other |
| May 31, 2016 | $14.50 | May 31, 2016 | — |
| May 16, 2016 | $0.30 | May 25, 2016 | Quarterly |
Wrqti brings Coca-Cola Europacific Partners data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Companies in the Consumer Defensive sector you can compare with Coca-Cola Europacific Partners :
Compare Coca-Cola Europacific Partners head-to-head with:
When available, the page shows quarterly and annual statements plus ratios such as PE, price to book, profit margin, and free cash flow. Latest financial period shown: December 2025.
Wrqti content depends on available data and third-party sources and may include delays or errors. Review official company filings and consult a licensed financial advisor before making investment decisions. Read the data methodology.